Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 26, 2012

View Archived Issues

New 5-lipoxygenase inhibitors claimed by Ranbaxy Laboratories

AZD-4694 PET detects Alzheimer's disease pathology in patients

Cancer vaccine shows activity in phase I/II trial

Kampo medicine reduces oxaliplatin-induced peripheral neuropathy in patients with cancer

Novel approach yields first small-molecule ligand for wild-type p53 DNA-binding domain

Panobinostat trial in colorectal cancer yields mixed results

Vanderbilt University patents new indoles

New insulin secretagogues prepared in Japan

Phase II trial investigates GS-7340 as part of a new treatment regimen

Amorcyte kicks off enrollment in phase II AMR-001 study

AC Immune and University of Basel enter research agreement

Sanwa Kagaku Kenkyusho presents novel glucokinase activators

Novel somatostatin receptor ligands reported

FDA approves gel for actinic keratosis

Incyte synthesizes novel PI3K-delta inhibitors

FDA clears updated Vytorin label

Bilastine launched in Brazil

New protease-activated PAR1 receptor antagonists disclosed

FDA expands Keppra indication

Neurocrine Biosciences product gets FDA fast track status

Spectrum Pharmaceuticals enters licensing agreement for Zevalin

CHMP issues opinion on Remicade for ulcerative colitis in children

Phase III afatinib trials begin in head and neck cancer

Targovax secures funding for cancer vaccine research

Initial phase III data show promise for tasimelteon

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.